FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Biotech Enterprise Capital Monitor – USA 02/2022”.
The Monitor is a month-to-month printed overview of enterprise capital developments within the US-Biotech sector.
As of the top of February 2022, we establish the next present VC developments within the US-Biotech sector:
- In 2022, general Biotech funding within the USA has reached USD 7,111m
- Prime 5 offers exceed USD 180m every, largest transaction amounted to USD 3,000m in Altos Labs
- RA Capital Administration (USA) leads the Prime 5 Traders (by deal quantity), adopted by OrbiMed (USA) and Catalio Capital Administration (USA)
- Central Nervous System dominates as the highest indication
To entry the total report, please click on right here.
By Dr. Mathias Schott and Sebastian Sommer